Apimeds Pharmaceuticals US, Inc. (APUS)
4.55
-0.07
(-1.52%)
USD |
NYAM |
Oct 14, 10:54
Apimeds Pharmaceuticals US Shareholders Equity (Quarterly) : 106.45M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 106.45M |
| March 31, 2026 | 126.52M |
| December 31, 2025 | 153.35M |
| September 30, 2025 | 8.161M |
| June 30, 2025 | 9.738M |
| March 31, 2025 | -1.760M |
| Date | Value |
|---|---|
| December 31, 2024 | -1.358M |
| September 30, 2024 | -1.046M |
| June 30, 2024 | -0.714M |
| March 31, 2024 | -0.2646M |
| December 31, 2023 | 0.0319M |
| September 30, 2023 | 0.1457M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 127.62M |
| Total Liabilities (Quarterly) | 21.18M |
| Debt to Equity Ratio | 0.1369 |
| Current Ratio | 0.5067 |
| Net Debt Paydown Yield | -20.17% |